0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968090
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The multidrug-resistant tuberculosis therapeutics market is evolving in response to urgent global health needs, driving innovation in treatments and delivery models. Biopharma leaders, policy-makers, and healthcare agencies are navigating a rapidly changing landscape, shaped by clinical breakthroughs, regulatory shifts, and procurement complexities.

Market Snapshot: Multidrug-Resistant Tuberculosis Therapeutics

The multidrug-resistant tuberculosis therapeutics market grew from USD 368.75 million in 2024 to USD 409.01 million in 2025. It is expected to continue growing at a CAGR of 11.19%, reaching USD 697.20 million by 2030. These figures reflect significant momentum in addressing complex resistance profiles and advancing targeted therapies across global regions. Market momentum is reinforced by the introduction of novel drug classes and evolving care models that better address patient and health system needs. Strategic investments in supply chain resilience and regulatory strategies further contribute to the market's robust outlook.

Scope & Segmentation

  • Drug Classes: Bedaquiline, Isoniazid, Levofloxacin, Linezolid, Rifampin
  • Treatment Types: Medication-based treatments, Non-medication therapies
  • Therapeutic Approaches: Combination treatments, Monotherapy
  • Drug Formulations: Capsules, Injectables, Tablets
  • Treatment Regimen Durations: Long-course regimens, Short-course regimens
  • Distribution Channels: Hospital pharmacies, Online pharmacies, Retail pharmacies
  • End Users: Hospitals, Online pharmacies, Retail pharmacies, Specialty clinics
  • Geographies: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Leading Companies: Abbott Laboratories, Abcam Limited, AstraZeneca, Aurobindo Pharma Ltd., Cipla Inc., Daiichi Sankyo Co., Ltd., Eli Lilly and Company, Endo International Plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson Services Inc., Lupin Limited, Macleods Pharmaceuticals Ltd., Merck & Co., Inc., Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Oxford Immunotec, Pfizer Inc., QureTech Bio AB, Sanofi SA, Santen Pharmaceutical Co., Ltd., Sequella, Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Key Takeaways for Senior Decision-Makers

  • Advances in drug development—such as the introduction of bedaquiline and host-directed therapies—are expanding the multidrug-resistant tuberculosis therapeutics market's portfolio and reshaping standard-of-care protocols.
  • Integrated care models, including digital adherence solutions and decentralized treatment, are being adopted widely to boost patient outcomes and offer new value opportunities for suppliers and healthcare providers.
  • Regional dynamics play a significant role; in Asia-Pacific and Europe, strategic investments in local manufacturing and digital tools are supporting resilient procurement and real-time resistance tracking.
  • Public-private partnerships between biopharma firms, academic institutions, and non-profits are accelerating therapy access and supporting scalable program deployment in high-burden regions.
  • Diversification in formulation choices—to include capsules, injectables, and tablets—caters to varied end-user requirements, ensuring that therapy delivery adapts to local infrastructure and patient adherence patterns.
  • Positioning product portfolios around bundled solutions that combine medication, monitoring, and analytics can drive competitive advantage for manufacturers, aligning with the growing emphasis on outcome-focused procurement.

Tariff Impact on Procurement and Supply Chains

The 2025 introduction of new United States tariffs will affect global access to core pharmaceuticals used in multidrug-resistant tuberculosis treatment. These tariffs are anticipated to raise the cost of active pharmaceutical ingredients and components, especially for manufacturers sourcing from U.S.-based suppliers. Downstream, procurement agencies may revamp supply contracts and seek diversification among suppliers,-potentially accelerating regional manufacturing initiatives and prompting more localized stockpiling strategies. Bundled offers that integrate drug supply with monitoring capabilities may help offset increased input costs for buyers and payers.

Methodology & Data Sources

This report synthesizes primary interviews with clinicians, procurement officers, and policy experts, paired with a thorough review of scientific publications, regulatory filings, clinical trial data, and proprietary distribution analytics. Cross-referencing and subject-matter validation further ensure reliability of segmentation and strategic findings.

Why This Report Matters

  • Supports decision-makers in identifying innovation opportunities and risk-mitigation strategies in the multidrug-resistant tuberculosis therapeutics market.
  • Equips procurement leaders and policy-makers with actionable insights on segmentation, regional market trends, and evolving regulatory requirements based on robust analysis.

Conclusion

The multidrug-resistant tuberculosis therapeutics market is advancing through coordinated innovation, strategic regional initiatives, and adaptive supply models. Stakeholders equipped with comprehensive, actionable intelligence are positioned for more effective therapy delivery and future market success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multidrug-resistant Tuberculosis Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Bedaquiline
8.3. Isoniazid
8.4. Levofloxacin
8.5. Linezolid
8.6. Rifampin
9. Multidrug-resistant Tuberculosis Therapeutics Market, by Treatment Type
9.1. Introduction
9.2. Medication-Based Treatments
9.3. Non-Medication Therapies
10. Multidrug-resistant Tuberculosis Therapeutics Market, by Therapeutic Approach
10.1. Introduction
10.2. Combination Treatments
10.3. Monotherapy
11. Multidrug-resistant Tuberculosis Therapeutics Market, by Drug Formulation
11.1. Introduction
11.2. Capsules
11.3. Injectables
11.4. Tablets
12. Multidrug-resistant Tuberculosis Therapeutics Market, by Treatment Regimen Duration
12.1. Introduction
12.2. Long-Course Regimens
12.3. Short-Course Regimens
13. Multidrug-resistant Tuberculosis Therapeutics Market, by End User
13.1. Introduction
13.2. Hospitals
13.3. Online Pharmacies
13.4. Retail Pharmacies
13.5. Specialty Clinics
14. Multidrug-resistant Tuberculosis Therapeutics Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacies
14.3. Online Pharmacies
14.4. Retail Pharmacies
15. Americas Multidrug-resistant Tuberculosis Therapeutics Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Multidrug-resistant Tuberculosis Therapeutics Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Multidrug-resistant Tuberculosis Therapeutics Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Abcam Limited
18.3.3. AstraZeneca
18.3.4. Aurobindo Pharma Ltd.
18.3.5. Cipla Inc.
18.3.6. Daiichi Sankyo Co., Ltd.
18.3.7. Eli Lilly and Company
18.3.8. Endo International Plc
18.3.9. F. Hoffmann-La Roche Ltd
18.3.10. GlaxoSmithKline plc
18.3.11. Johnson & Johnson Services Inc.
18.3.12. Lupin Limited
18.3.13. Macleods Pharmaceuticals Ltd.
18.3.14. Merck & Co., Inc.
18.3.15. Mylan N.V.
18.3.16. Novartis AG
18.3.17. Otsuka Pharmaceutical Co., Ltd.
18.3.18. Oxford Immunotec
18.3.19. Pfizer Inc.
18.3.20. QureTech Bio AB
18.3.21. Sanofi SA
18.3.22. Santen Pharmaceutical Co., Ltd.
18.3.23. Sequella, Inc.
18.3.24. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION-BASED TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY NON-MEDICATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COMBINATION TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LONG-COURSE REGIMENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SHORT-COURSE REGIMENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 53. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 60. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 95. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 96. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 98. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. GERMANY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 103. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 105. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. FRANCE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 117. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 119. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. ITALY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 124. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 125. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 126. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SPAIN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 152. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 154. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 165. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 166. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 167. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 168. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. QATAR MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 173. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 175. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. FINLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 194. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 195. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 196. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. TURKEY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. TURKEY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. TURKEY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 201. TURKEY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 202. TURKEY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 203. TURKEY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. TURKEY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 215. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 217. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NORWAY MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 221. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 222. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. POLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 241. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 244. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 245. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 246. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 251. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 252. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 253. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 257. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 258. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 259. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT REGIMEN DURATION, 2018-2030 (USD MILLION)
TABLE 260. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Multidrug-resistant Tuberculosis Therapeutics market report include:
  • Abbott Laboratories
  • Abcam Limited
  • AstraZeneca
  • Aurobindo Pharma Ltd.
  • Cipla Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Oxford Immunotec
  • Pfizer Inc.
  • QureTech Bio AB
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd.
  • Sequella, Inc.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 409.01 Million
Forecasted Market Value ( USD ) by 2030 $ 697.2 Million
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Tuberculosis Treatment Drugs - Global Strategic Business Report - Product Image

Tuberculosis Treatment Drugs - Global Strategic Business Report

  • Report
  • 369 Pages
  • Global
From
EUR$5,850USDGBP
Tuberculosis Therapeutics Market Report 2025 - Product Image

Tuberculosis Therapeutics Market Report 2025

  • Report
  • 175 Pages
  • Global
From
EUR$4,490USDGBP
Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 178 Pages
  • Global
From
EUR$4,500USDGBP
Tuberculosis Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Treatment Regimen, Tuberculosis Type - Global Forecast to 2030 - Product Image

Tuberculosis Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Treatment Regimen, Tuberculosis Type - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more